3 research outputs found
Dynamics of cytokine profile in patients with abdominal sepsis caused by pancreonecrosis
Acute pancreatitis is one of the most pressing problems of modern pancreatology, according to the authors ranks first among surgical pathologies.The aim of this study was to evaluate the dynamics of cytokine profile in patients with abdominal sepsis caused by pancreatic necrosis.Materials and methods.The study was conducted in 12 patients diagnosed with abdominal sepsis caused by pancreatic necrosis, in the period from 2017 to 2020 who were treated in medical hospitals in Chernivtsi and Ternopil. The control group consisted of 17 patients without signs of abdominal sepsis and acute surgical pathology. Both groups were representative by age, sex, comorbidities, risk factors. Determination of experimental parameters in the blood of patients was performed in the postoperative period (the results were evaluated before surgery, on the first and tenth days of the postoperative period).Research results and their discussion.In patients with abdominal sepsis, a violation of the mechanisms of cell adhesion and costimulatory-cooperative interaction of immunocompetent cells was observed in the preoperative period, as indicated by the low level of CD11a + and CD162 + expression on them. The decrease in the content of IL-6 in the blood with a slight progressive increase in the level of IL-4 corresponds to a moderate imbalance of cytokine regulation of the immune response
Influence of disposable relaparotomy and programmed sanation on the expression and dynamics of clusters determinations on immunocompetent cells of patients with abdominal sepsis caused by severe peritonitis
Relaparotomy in the treatment of postoperative complications of abdominal surgery remains a difficult problem of modern surgery.To evaluate the prognostic value of expression clusters of determination on immunocompetent cells of patients, the dynamics of HLA-DR + molecules and cytokines in the blood of patients with abdominal sepsis caused by severe peritonitis, as well as abscesses and phlegmons for postoperative period.Materials and methods.The study was conducted in 40 patients diagnosed with abdominal sepsis in the period from 2017-2020, which was treated in medical institutions of Chernivtsi and Ternopil in Ukraine, and which were divided into control and research groups. The control group consisted of 17 patients without signs of abdominal sepsis and acute surgical pathology. Determination of the expression of determination clusters such as CD11a, CD162, CD95, CD16 on immunocompetent cells, and the study of the dynamics of expression of HLA-DR + molecules and the content of cytokines IL-2, IL-4, IL-6 in the blood of patients was performed in the postoperative period. Both groups were representative by age, sex, comorbidities, risk factors. Determination of experimental parameters in the blood of patients was performed in the postoperative period (the results were evaluated before surgery, on the first, third, seventh, and on the fourteenth day of the postoperative period).Research results and their discussionIn patients with abdominal sepsis caused by severe peritonitis, the expression of HLA-DR + molecules on immunocompetent cells increases, which to some extent indicates an intensification of Ξ³-interferon synthesis. At the same time, there is a sharp decrease in the content of IL-2 in the blood - the main regulator of a specific immune response
ΠΠΎΡΠ»ΡΠ΄ΠΆΠ΅Π½Π½Ρ Π³ΡΡΡΠΎΠ»ΠΎΠ³ΡΡΠ½ΠΎΡ ΡΠ° Π½Π΅ΠΊΡΠΎΠ·Π°ΠΏΠ°Π»ΡΠ½ΠΎΡ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ ΠΏΠ΅ΡΡΠ½ΠΊΠΈ Ρ ΡΠΎΡΠΌΡΠ²Π°Π½Π½Ρ ΡΠΈΠ½Π΄ΡΠΎΠΌΡ ΠΏΠΎΡΡΠ°Π»ΡΠ½ΠΎΡ Π³ΡΠΏΠ΅ΡΡΠ΅Π½Π·ΡΡ.
Background. Liver cirrhosis is the most often cause of the portal hypertension syndrome development, though structural and morphological liver remodeling usually begins on the stage of chronic hepatitis. Morphologic patterns of the development of portal hypertension syndrome on the pre-clinical stage are still poorly investigated. Objective. To determine the histological and necroinflammatory activity of the liver in patients with portal hypertension. Methods. Patients were divided into four groups: I group (n=38) β chronic hepatitis without clinical signs of portal hypertension; II group (n=42) - chronic hepatitis transforming to cirrhosis with clinical signs of portal hypertension (varicose veins of the esophagus and/or the cardia, splenomegaly, ascitis); III group (n=34) β complicated portal hypertension on the background of liver cirrhosis (bleeding from the varices of the esophagus and/or the cardia, hypersplenism); control group (n=30) - physically healthy individuals aged 23-37 years. An integrated evaluation of the liver histological and necroinflammatory activity through the set of laboratory tests was performed (the method of βFibroTest-ActiTestβ; immunofermental analysis of L-FABP concentration). Results. It is found that the patients with pre-clinical stage of portal hypertension syndrome show portal and periportal fibrosis with single septa, and the patients with clinical stages of portal hypertension show portal and periportal cirrhosis with multiple septa. Patients with the complications of portal hypertension show cirrhosis of the liver. With the increase of the necroinflammatory activity the portal pressure increases directly. This fact was confirmed with the increase of L-FABP protein level in the plasma, along with the increase of the actitest results. Conclusion. The diagnostic methodic of βFibroTest-ActiTestβ and the plasma level of L-FABP are the modern models for chronic liver disease histological and necroinflammatory activity evaluation, though there is still the need to determine the correlation with the direct histological picture of liver biopsy.Π¦ΠΈΡΡΠΎΠ· ΠΏΠ΅ΡΠ΅Π½ΠΈ ΡΠ²Π»ΡΠ΅ΡΡΡ Π½Π°ΠΈΠ±ΠΎΠ»Π΅Π΅ ΡΠ°ΡΡΠΎΠΉ ΠΏΡΠΈΡΠΈΠ½ΠΎΠΉ ΡΠ°Π·Π²ΠΈΡΠΈΡ ΡΠΈΠ½Π΄ΡΠΎΠΌΠ° ΠΏΠΎΡΡΠ°Π»ΡΠ½ΠΎΠΉ Π³ΠΈΠΏΠ΅ΡΡΠ΅Π½Π·ΠΈΠΈ, Ρ
ΠΎΡΡ ΡΡΡΡΠΊΡΡΡΠ½ΡΠ΅ ΠΈ ΠΌΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΏΠ΅ΡΠ΅ΡΡΡΠΎΠΉΠΊΠΈ ΠΏΠ΅ΡΠ΅Π½ΠΈ ΠΎΠ±ΡΡΠ½ΠΎ Π½Π°ΡΠΈΠ½Π°ΡΡΡΡ Π΅ΡΠ΅ Π½Π° ΡΡΠ°Π΄ΠΈΠΈ Ρ
ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ Π³Π΅ΠΏΠ°ΡΠΈΡΠ°. ΠΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠ΅ Π·Π°ΠΊΠΎΠ½ΠΎΠΌΠ΅ΡΠ½ΠΎΡΡΠΈ ΡΠ°Π·Π²ΠΈΡΠΈΡ ΡΠΈΠ½Π΄ΡΠΎΠΌΠ° ΠΏΠΎΡΡΠ°Π»ΡΠ½ΠΎΠΉ Π³ΠΈΠΏΠ΅ΡΡΠ΅Π½Π·ΠΈΠΈ Π½Π° Π΄ΠΎΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΡΠ°Π΄ΠΈΠΈ Π²ΡΠ΅ Π΅ΡΠ΅ Π½Π΅Π΄ΠΎΡΡΠ°ΡΠΎΡΠ½ΠΎ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½Ρ. Π¦Π΅Π»Ρ β ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΠ΅ Π³ΠΈΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΈ Π½Π΅ΠΊΡΠΎΠ²ΠΎΡΠΏΠ°Π»ΠΈΡΠ΅Π»ΡΠ½ΠΎΠΉ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΠΏΠ΅ΡΠ΅Π½ΠΈ Ρ Π±ΠΎΠ»ΡΠ½ΡΡ
Ρ ΡΠΈΠ½Π΄ΡΠΎΠΌΠΎΠΌ ΠΏΠΎΡΡΠ°Π»ΡΠ½ΠΎΠΉ Π³ΠΈΠΏΠ΅ΡΡΠ΅Π½Π·ΠΈΠΈ. ΠΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² ΡΠ°Π·Π΄Π΅Π»ΠΈΠ»ΠΈ Π½Π° ΡΠ΅ΡΡΡΠ΅ Π³ΡΡΠΏΠΏΡ: I Π³ΡΡΠΏΠΏΠ° (n=38) - Ρ
ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΈΠΉ Π³Π΅ΠΏΠ°ΡΠΈΡ Π±Π΅Π· ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΏΡΠΎΡΠ²Π»Π΅Π½ΠΈΠΉ ΡΠΈΠ½Π΄ΡΠΎΠΌΠ° ΠΏΠΎΡΡΠ°Π»ΡΠ½ΠΎΠΉ Π³ΠΈΠΏΠ΅ΡΡΠ΅Π½Π·ΠΈΠΈ; II Π³ΡΡΠΏΠΏΠ° (n=42) - Ρ
ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΈΠΉ Π³Π΅ΠΏΠ°ΡΠΈΡ Ρ ΡΡΠ°Π½ΡΡΠΎΡΠΌΠ°ΡΠΈΠ΅ΠΉ Π² ΡΠΈΡΡΠΎΠ· Ρ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΠΌΠΈ ΠΏΡΠΎΡΠ²Π»Π΅Π½ΠΈΡΠΌΠΈ ΡΠΈΠ½Π΄ΡΠΎΠΌΠ° ΠΏΠΎΡΡΠ°Π»ΡΠ½ΠΎΠΉ Π³ΠΈΠΏΠ΅ΡΡΠ΅Π½Π·ΠΈΠΈ (Π²Π°ΡΠΈΠΊΠΎΠ·Π½ΠΎΠ΅ ΡΠ°ΡΡΠΈΡΠ΅Π½ΠΈΠ΅ Π²Π΅Π½ ΠΏΠΈΡΠ΅Π²ΠΎΠ΄Π° ΠΈ/ΠΈΠ»ΠΈ ΠΊΠ°ΡΠ΄ΠΈΠΈ, ΡΠΏΠ»Π΅Π½ΠΎΠΌΠ΅Π³Π°Π»ΠΈΡ, Π°ΡΡΠΈΡ); III Π³ΡΡΠΏΠΏΠ° (n=34) - ΠΎΡΠ»ΠΎΠΆΠ½Π΅Π½Π½Π°Ρ ΠΏΠΎΡΡΠ°Π»ΡΠ½Π°Ρ Π³ΠΈΠΏΠ΅ΡΡΠ΅Π½Π·ΠΈΡ Π½Π° ΠΎΡΠ½ΠΎΠ²Π΅ ΡΠΈΡΡΠΎΠ·Π° ΠΏΠ΅ΡΠ΅Π½ΠΈ (ΠΊΡΠΎΠ²ΠΎΡΠ΅ΡΠ΅Π½ΠΈΠ΅ ΠΈΠ· Π²Π°ΡΠΈΠΊΠΎΠ·Π½ΠΎ ΡΠ°ΡΡΠΈΡΠ΅Π½Π½ΡΡ
Π²Π΅Π½ ΠΏΠΈΡΠ΅Π²ΠΎΠ΄Π° ΠΈ/ΠΈΠ»ΠΈ ΠΊΠ°ΡΠ΄ΠΈΠΈ, Π³ΠΈΠΏΠ΅ΡΡΠΏΠ»Π΅Π½ΠΈΠ·ΠΌ); ΠΊΠΎΠ½ΡΡΠΎΠ»ΡΠ½Π°Ρ Π³ΡΡΠΏΠΏΠ° (n=30) - ΡΠΈΠ·ΠΈΡΠ΅ΡΠΊΠΈ Π·Π΄ΠΎΡΠΎΠ²ΡΠ΅ Π»ΠΈΡΠ° Π²ΠΎΠ·ΡΠ°ΡΡΠ΅ 23-37 Π»Π΅Ρ. ΠΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½Π° ΠΈΠ½ΡΠ΅Π³ΡΠ°Π»ΡΠ½Π°Ρ ΠΎΡΠ΅Π½ΠΊΠ° ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΡ Π³ΠΈΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠΉ, Π½Π΅ΠΊΡΠΎΠ²ΠΎΡΠΏΠ°Π»ΠΈΡΠ΅Π»ΡΠ½ΠΎΠΉ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΠΏΠ΅ΡΠ΅Π½ΠΈ Ρ ΠΏΠΎΠΌΠΎΡΡΡ Π½Π°Π±ΠΎΡΠΎΠ² Π»Π°Π±ΠΎΡΠ°ΡΠΎΡΠ½ΡΡ
ΡΠ΅ΡΡΠΎΠ² (ΠΌΠ΅ΡΠΎΠ΄ΠΈΠΊΠ° Β«FibroTest-ActiTestΒ»; ΠΈΠΌΠΌΡΠ½ΠΎΡΠ΅ΡΠΌΠ΅Π½ΡΠ½ΡΠΉ Π°Π½Π°Π»ΠΈΠ· ΡΡΠΎΠ²Π½Ρ L-FABP). Π£ΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½ΠΎ, ΡΡΠΎ Ρ Π±ΠΎΠ»ΡΠ½ΡΡ
Π½Π° Π΄ΠΎΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΡΠ°Π΄ΠΈΠΈ ΡΠΈΠ½Π΄ΡΠΎΠΌΠ° ΠΏΠΎΡΡΠ°Π»ΡΠ½ΠΎΠΉ Π³ΠΈΠΏΠ΅ΡΡΠ΅Π½Π·ΠΈΠΈ ΠΈΠΌΠ΅Π΅Ρ ΠΌΠ΅ΡΡΠΎ ΠΏΠΎΡΡΠ°Π»ΡΠ½ΡΠΉ ΠΈ ΠΏΠ΅ΡΠΈΠΏΠΎΡΡΠ°Π»ΡΠ½ΡΠΉ ΡΠΈΠ±ΡΠΎΠ· Ρ Π΅Π΄ΠΈΠ½ΠΈΡΠ½ΡΠΌΠΈ ΡΠ΅ΠΏΡΠ°ΠΌΠΈ, Ρ Π±ΠΎΠ»ΡΠ½ΡΡ
Ρ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΠΎΡΠΌΠΎΠΉ ΠΏΠΎΡΡΠ°Π»ΡΠ½ΠΎΠΉ Π³ΠΈΠΏΠ΅ΡΡΠ΅Π½Π·ΠΈΠΈ - ΠΏΠΎΡΡΠ°Π»ΡΠ½ΡΠΉ ΠΈ ΠΏΠ΅ΡΠΈΠΏΠΎΡΡΠ°Π»ΡΠ½ΡΠΉ ΡΠΈΡΡΠΎΠ· Ρ ΠΌΠ½ΠΎΠΆΠ΅ΡΡΠ²Π΅Π½Π½ΡΠΌΠΈ ΡΠ΅ΠΏΡΠ°ΠΌΠΈ, Π° Ρ Π±ΠΎΠ»ΡΠ½ΡΡ
Ρ ΠΎΡΠ»ΠΎΠΆΠ½Π΅Π½Π½ΠΎΠΉ ΠΏΠΎΡΡΠ°Π»ΡΠ½ΠΎΠΉ Π³ΠΈΠΏΠ΅ΡΡΠ΅Π½Π·ΠΈΠ΅ΠΉ - ΡΠΈΡΡΠΎΠ· ΠΏΠ΅ΡΠ΅Π½ΠΈ. Π‘ ΡΠΎΡΡΠΎΠΌ ΡΡΠ΅ΠΏΠ΅Π½ΠΈ Π½Π΅ΠΊΡΠΎΠ²ΠΎΡΠΏΠ°Π»ΠΈΡΠ΅Π»ΡΠ½ΠΎΠΉ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΠΏΡΡΠΌΠΎ ΠΏΡΠΎΠΏΠΎΡΡΠΈΠΎΠ½Π°Π»ΡΠ½ΠΎ ΡΠ°ΡΡΠ΅Ρ Π΄Π°Π²Π»Π΅Π½ΠΈΠ΅ Π² ΡΠΈΡΡΠ΅ΠΌΠ΅ ΠΏΠΎΡΡΠ°Π»ΡΠ½ΠΎΠΉ Π²Π΅Π½Ρ. Π ΠΏΠΎΡΠ»Π΅Π΄Π½Π΅ΠΌ ΡΠ²ΠΈΠ΄Π΅ΡΠ΅Π»ΡΡΡΠ²ΡΠ΅Ρ Π½Π°ΡΠ°ΡΡΠ°Π½ΠΈΠ΅ ΠΊΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΠΈ ΠΏΡΠΎΡΠ΅ΠΈΠ½Π° L - FABP Π² ΠΏΠ»Π°Π·ΠΌΠ΅ ΠΊΡΠΎΠ²ΠΈ Π² Π³ΡΡΠΏΠΏΠ°Ρ
ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Π½Π°ΡΡΠ΄Ρ Ρ ΡΠΎΡΡΠΎΠΌ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»Π΅ΠΉ Π°ΠΊΡΠΈΡΠ΅ΡΡΠ°. ΠΠΈΠ°Π³Π½ΠΎΡΡΠΈΡΠ΅ΡΠΊΠ°Ρ ΠΌΠ΅ΡΠΎΠ΄ΠΈΠΊΠ° Β«FibroTest-ActiTestΒ» ΠΈ ΡΡΠΎΠ²Π΅Π½Ρ L-FABP Π² ΠΏΠ»Π°Π·ΠΌΠ΅ ΡΠ²Π»ΡΡΡΡΡ ΡΠΎΠ²ΡΠ΅ΠΌΠ΅Π½Π½ΡΠΌΠΈ ΠΌΠΎΠ΄Π΅Π»ΡΠΌΠΈ ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΡ Π³ΠΈΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΈ Π½Π΅ΠΊΡΠΎΠ²ΠΎΡΠΏΠ°Π»ΠΈΡΠ΅Π»ΡΠ½ΠΎΠΉ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ Ρ
ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΈΡ
Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠΉ ΠΏΠ΅ΡΠ΅Π½ΠΈ, Ρ
ΠΎΡΡ Π΄ΠΎ ΡΠΈΡ
ΠΏΠΎΡ ΡΠΎΡ
ΡΠ°Π½ΡΠ΅ΡΡΡ Π½Π΅ΠΎΠ±Ρ
ΠΎΠ΄ΠΈΠΌΠΎΡΡΡ Π² ΡΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½ΠΈΠΈ ΠΊΠΎΡΡΠ΅Π»ΡΡΠΈΠΈ Ρ Π½Π΅ΠΏΠΎΡΡΠ΅Π΄ΡΡΠ²Π΅Π½Π½ΠΎΠΉ Π³ΠΈΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΊΠ°ΡΡΠΈΠ½ΠΎΠΉ Π±ΠΈΠΎΠΏΡΠΈΠΈ ΠΏΠ΅ΡΠ΅Π½ΠΈ.Π¦ΠΈΡΠΎΠ· ΠΏΠ΅ΡΡΠ½ΠΊΠΈ Ρ Π½Π°ΠΉΠ±ΡΠ»ΡΡ ΡΠ°ΡΡΠΎΡ ΠΏΡΠΈΡΠΈΠ½ΠΎΡ ΡΠΎΠ·Π²ΠΈΡΠΊΡ ΡΠΈΠ½Π΄ΡΠΎΠΌΡ ΠΏΠΎΡΡΠ°Π»ΡΠ½ΠΎΡ Π³ΡΠΏΠ΅ΡΡΠ΅Π½Π·ΡΡ, Ρ
ΠΎΡΠ° ΡΡΡΡΠΊΡΡΡΠ½Ρ ΡΠ° ΠΌΠΎΡΡΠΎΠ»ΠΎΠ³ΡΡΠ½Ρ ΠΏΠ΅ΡΠ΅Π±ΡΠ΄ΠΎΠ²ΠΈ ΠΏΠ΅ΡΡΠ½ΠΊΠΈ Π·Π°Π·Π²ΠΈΡΠ°ΠΉ ΠΏΠΎΡΠΈΠ½Π°ΡΡΡΡΡ ΡΠ΅ Π½Π° ΡΡΠ°Π΄ΡΡ Ρ
ΡΠΎΠ½ΡΡΠ½ΠΎΠ³ΠΎ Π³Π΅ΠΏΠ°ΡΠΈΡΡ. ΠΠΎΡΡΠΎΠ»ΠΎΠ³ΡΡΠ½Ρ Π·Π°ΠΊΠΎΠ½ΠΎΠΌΡΡΠ½ΠΎΡΡΡ ΡΠΎΠ·Π²ΠΈΡΠΊΡ ΡΠΈΠ½Π΄ΡΠΎΠΌΡ ΠΏΠΎΡΡΠ°Π»ΡΠ½ΠΎΡ Π³ΡΠΏΠ΅ΡΡΠ΅Π½Π·ΡΡ Π½Π° Π΄ΠΎΠΊΠ»ΡΠ½ΡΡΠ½ΡΠΉ ΡΡΠ°Π΄ΡΡ Π²ΡΠ΅ ΡΠ΅ Π½Π΅Π΄ΠΎΡΡΠ°ΡΠ½ΡΠΎ Π΄ΠΎΡΠ»ΡΠ΄ΠΆΠ΅Π½Ρ. ΠΠ΅ΡΠ° - Π²ΠΈΠ·Π½Π°ΡΠ΅Π½Π½Ρ Π³ΡΡΡΠΎΠ»ΠΎΠ³ΡΡΠ½ΠΎΡ ΡΠ° Π½Π΅ΠΊΡΠΎΠ·Π°ΠΏΠ°Π»ΡΠ½ΠΎΡ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ ΠΏΠ΅ΡΡΠ½ΠΊΠΈ Ρ Ρ
Π²ΠΎΡΠΈΡ
Π· ΡΠΈΠ½Π΄ΡΠΎΠΌΠΎΠΌ ΠΏΠΎΡΡΠ°Π»ΡΠ½ΠΎΡ Π³ΡΠΏΠ΅ΡΡΠ΅Π½Π·ΡΡ. ΠΠΈΠΊΠΎΡΠΈΡΡΠ°Π½ΠΎ ΡΠ½ΡΠ΅Π³ΡΠ°Π»ΡΠ½Ρ ΠΎΡΡΠ½ΠΊΡ Π²ΠΈΠ·Π½Π°ΡΠ΅Π½Π½Ρ Π³ΡΡΡΠΎΠ»ΠΎΠ³ΡΡΠ½ΠΎΡ, Π½Π΅ΠΊΡΠΎΠ·Π°ΠΏΠ°Π»ΡΠ½ΠΎΡ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ ΠΏΠ΅ΡΡΠ½ΠΊΠΈ Π·Π° Π΄ΠΎΠΏΠΎΠΌΠΎΠ³ΠΎΡ Π½Π°Π±ΠΎΡΡΠ² Π»Π°Π±ΠΎΡΠ°ΡΠΎΡΠ½ΠΈΡ
ΡΠ΅ΡΡΡΠ² (ΠΌΠ΅ΡΠΎΠ΄ΠΈΠΊΠ° βFibroTest-ActiTestβ; ΡΠΌΡΠ½ΠΎΡΠ΅ΡΠΌΠ΅Π½ΡΠ½ΠΈΠΉ Π°Π½Π°Π»ΡΠ· ΡΡΠ²Π½Ρ L-FABP). ΠΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½ΠΎ, ΡΠΎ Ρ Ρ
Π²ΠΎΡΠΈΡ
Π½Π° Π΄ΠΎΠΊΠ»ΡΠ½ΡΡΠ½ΡΠΉ ΡΡΠ°Π΄ΡΡ ΡΠΈΠ½Π΄ΡΠΎΠΌΡ ΠΏΠΎΡΡΠ°Π»ΡΠ½ΠΎΡ Π³ΡΠΏΠ΅ΡΡΠ΅Π½Π·ΡΡ ΠΌΠ°Ρ ΠΌΡΡΡΠ΅ ΠΏΠΎΡΡΠ°Π»ΡΠ½ΠΈΠΉ Ρ ΠΏΠ΅ΡΠΈΠΏΠΎΡΡΠ°Π»ΡΠ½ΠΈΠΉ ΡΡΠ±ΡΠΎΠ· Π· ΠΏΠΎΠΎΠ΄ΠΈΠ½ΠΎΠΊΠΈΠΌΠΈ ΡΠ΅ΠΏΡΠ°ΠΌΠΈ, Ρ Ρ
Π²ΠΎΡΠΈΡ
Π· ΠΊΠ»ΡΠ½ΡΡΠ½ΠΎΡ ΡΠΎΡΠΌΠΎΡ ΠΏΠΎΡΡΠ°Π»ΡΠ½ΠΎΡ Π³ΡΠΏΠ΅ΡΡΠ΅Π½Π·ΡΡ β ΠΏΠΎΡΡΠ°Π»ΡΠ½ΠΈΠΉ Ρ ΠΏΠ΅ΡΠΈΠΏΠΎΡΡΠ°Π»ΡΠ½ΠΈΠΉ ΡΠΈΡΠΎΠ· Π· ΠΌΠ½ΠΎΠΆΠΈΠ½Π½ΠΈΠΌΠΈ ΡΠ΅ΠΏΡΠ°ΠΌΠΈ, Π° Ρ Ρ
Π²ΠΎΡΠΈΡ
Π· ΡΡΠΊΠ»Π°Π΄Π½Π΅Π½ΠΎΡ ΠΏΠΎΡΡΠ°Π»ΡΠ½ΠΎΡ Π³ΡΠΏΠ΅ΡΡΠ΅Π½Π·ΡΡΡ β ΡΠΈΡΠΎΠ· ΠΏΠ΅ΡΡΠ½ΠΊΠΈ. ΠΡ Π·ΡΠΎΡΡΠ°Π½Π½ΡΠΌ ΡΡΡΠΏΠ΅Π½Ρ Π½Π΅ΠΊΡΠΎΠ·Π°ΠΏΠ°Π»ΡΠ½ΠΎΡ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ ΠΏΡΡΠΌΠΎ ΠΏΡΠΎΠΏΠΎΡΡΡΠΉΠ½ΠΎ Π·ΡΠΎΡΡΠ°Ρ ΡΠΈΡΠΊ Ρ ΡΠΈΡΡΠ΅ΠΌΡ ΠΏΠΎΡΡΠ°Π»ΡΠ½ΠΎΡ Π²Π΅Π½ΠΈ. ΠΡΠΎ ΠΎΡΡΠ°Π½Π½Ρ ΡΠ²ΡΠ΄ΡΠΈΡΡ Π½Π°ΡΠΎΡΡΠ°Π½Π½Ρ ΠΊΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΡΡ ΠΏΡΠΎΡΠ΅ΡΠ½Ρ L-FABP Ρ ΠΏΠ»Π°Π·ΠΌΡ ΠΊΡΠΎΠ²Ρ Ρ Π³ΡΡΠΏΠ°Ρ
ΠΏΠ°ΡΡΡΠ½ΡΡΠ² ΠΏΠΎΡΡΠ΄ Π·Ρ Π·ΡΠΎΡΡΠ°Π½Π½ΡΠΌ ΠΏΠΎΠΊΠ°Π·Π½ΠΈΠΊΡΠ² Π°ΠΊΡΡΡΠ΅ΡΡΡ. ΠΡΠ°Π³Π½ΠΎΡΡΠΈΡΠ½Π° ΠΌΠ΅ΡΠΎΠ΄ΠΈΠΊΠ° βFibroTest-ActiTestβ ΡΠ° ΡΡΠ²Π΅Π½Ρ L-FABP Ρ ΠΏΠ»Π°Π·ΠΌΡ Ρ ΡΡΡΠ°ΡΠ½ΠΈΠΌΠΈ ΠΌΠΎΠ΄Π΅Π»ΡΠΌΠΈ Π²ΠΈΠ·Π½Π°ΡΠ΅Π½Π½Ρ Π³ΡΡΡΠΎΠ»ΠΎΠ³ΡΡΠ½ΠΎΡ ΡΠ° Π½Π΅ΠΊΡΠΎΠ·Π°ΠΏΠ°Π»ΡΠ½ΠΎΡ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ Ρ
ΡΠΎΠ½ΡΡΠ½ΠΈΡ
Π·Π°Ρ
Π²ΠΎΡΡΠ²Π°Π½Ρ ΠΏΠ΅ΡΡΠ½ΠΊΠΈ